JP4589233B2 - 歯周病と歯髄疾患の治療剤と治療方法 - Google Patents
歯周病と歯髄疾患の治療剤と治療方法 Download PDFInfo
- Publication number
- JP4589233B2 JP4589233B2 JP2005513867A JP2005513867A JP4589233B2 JP 4589233 B2 JP4589233 B2 JP 4589233B2 JP 2005513867 A JP2005513867 A JP 2005513867A JP 2005513867 A JP2005513867 A JP 2005513867A JP 4589233 B2 JP4589233 B2 JP 4589233B2
- Authority
- JP
- Japan
- Prior art keywords
- bdnf
- cells
- expression level
- graph
- mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000003239 periodontal effect Effects 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title abstract description 30
- 201000010099 disease Diseases 0.000 title abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 10
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 230000001172 regenerating effect Effects 0.000 claims abstract description 6
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 162
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 162
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 162
- 210000000988 bone and bone Anatomy 0.000 claims description 50
- 210000001519 tissue Anatomy 0.000 claims description 36
- 210000002379 periodontal ligament Anatomy 0.000 claims description 32
- 210000000981 epithelium Anatomy 0.000 claims description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract description 144
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract description 36
- 239000003900 neurotrophic factor Substances 0.000 abstract description 36
- 230000017423 tissue regeneration Effects 0.000 abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 208
- 230000014509 gene expression Effects 0.000 description 181
- 108020004999 messenger RNA Proteins 0.000 description 177
- 230000009471 action Effects 0.000 description 110
- 102000015336 Nerve Growth Factor Human genes 0.000 description 108
- 108090000742 Neurotrophin 3 Proteins 0.000 description 84
- 102100029268 Neurotrophin-3 Human genes 0.000 description 84
- 108090000099 Neurotrophin-4 Proteins 0.000 description 57
- 102000003683 Neurotrophin-4 Human genes 0.000 description 47
- 239000002609 medium Substances 0.000 description 47
- 238000001962 electrophoresis Methods 0.000 description 45
- 230000000694 effects Effects 0.000 description 41
- 238000010586 diagram Methods 0.000 description 40
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 37
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 37
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 33
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 33
- 102000004264 Osteopontin Human genes 0.000 description 32
- 108010081689 Osteopontin Proteins 0.000 description 32
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 31
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 31
- 239000003550 marker Substances 0.000 description 28
- 102000012422 Collagen Type I Human genes 0.000 description 25
- 108010022452 Collagen Type I Proteins 0.000 description 25
- 239000000463 material Substances 0.000 description 25
- 210000004268 dentin Anatomy 0.000 description 23
- 238000000692 Student's t-test Methods 0.000 description 22
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 22
- 238000012353 t test Methods 0.000 description 22
- 238000011069 regeneration method Methods 0.000 description 21
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 19
- 230000006820 DNA synthesis Effects 0.000 description 18
- 230000007547 defect Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 102000004067 Osteocalcin Human genes 0.000 description 16
- 108090000573 Osteocalcin Proteins 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 230000008929 regeneration Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 210000002950 fibroblast Anatomy 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 11
- 229930182555 Penicillin Natural products 0.000 description 11
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 11
- 229940049954 penicillin Drugs 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 229960005322 streptomycin Drugs 0.000 description 11
- 102100033857 Neurotrophin-4 Human genes 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 229940053128 nerve growth factor Drugs 0.000 description 10
- 229940032018 neurotrophin 3 Drugs 0.000 description 10
- 229940097998 neurotrophin 4 Drugs 0.000 description 10
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 9
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 9
- 229960003942 amphotericin b Drugs 0.000 description 9
- 238000000528 statistical test Methods 0.000 description 9
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 8
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 101150111783 NTRK1 gene Proteins 0.000 description 7
- 101150117329 NTRK3 gene Proteins 0.000 description 7
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 6
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 6
- 102100029792 Dentin sialophosphoprotein Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 101000865404 Homo sapiens Dentin sialophosphoprotein Proteins 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 210000001968 dental pulp cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004195 gingiva Anatomy 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000879 optical micrograph Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000010478 bone regeneration Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 229920001342 Bakelite® Polymers 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 239000004637 bakelite Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003953 foreskin Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000005919 time-dependent effect Effects 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000004262 dental pulp cavity Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000001648 gingival epithelial cell Anatomy 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000005888 Periodontal Pocket Diseases 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 208000008312 Tooth Loss Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000004763 bicuspid Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000019786 dental pulp disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- -1 present in the brain Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004357 third molar Anatomy 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- PMJHNEFCWLUZBC-UHFFFAOYSA-N 4-(4-amino-3-methylphenyl)-2,6,6-trimethylcyclohexa-1,3-dien-1-amine Chemical compound CC1=C(N)C(C)(C)CC(C=2C=C(C)C(N)=CC=2)=C1 PMJHNEFCWLUZBC-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 102400001059 Dentin sialoprotein Human genes 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 1
- 101000739876 Homo sapiens Brain-derived neurotrophic factor Proteins 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 108010088492 dentin sialophosphoprotein Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002256 epithelial attachment Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 102000051542 human BDNF Human genes 0.000 description 1
- 102000046917 human NGF Human genes 0.000 description 1
- 102000057714 human NTF3 Human genes 0.000 description 1
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003316719 | 2003-09-09 | ||
| JP2003316719 | 2003-09-09 | ||
| PCT/JP2004/013023 WO2005025605A1 (ja) | 2003-09-09 | 2004-09-08 | 歯周病と歯髄疾患の治療剤と治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010143538A Division JP5313209B2 (ja) | 2003-09-09 | 2010-06-24 | 歯周病と歯髄疾患の治療剤と治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2005025605A1 JPWO2005025605A1 (ja) | 2007-11-08 |
| JP4589233B2 true JP4589233B2 (ja) | 2010-12-01 |
Family
ID=34308464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005513867A Expired - Fee Related JP4589233B2 (ja) | 2003-09-09 | 2004-09-08 | 歯周病と歯髄疾患の治療剤と治療方法 |
| JP2010143538A Expired - Fee Related JP5313209B2 (ja) | 2003-09-09 | 2010-06-24 | 歯周病と歯髄疾患の治療剤と治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010143538A Expired - Fee Related JP5313209B2 (ja) | 2003-09-09 | 2010-06-24 | 歯周病と歯髄疾患の治療剤と治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8158752B2 (enExample) |
| EP (3) | EP1671641B1 (enExample) |
| JP (2) | JP4589233B2 (enExample) |
| CN (3) | CN102526706B (enExample) |
| AU (1) | AU2004271843B2 (enExample) |
| RU (1) | RU2336089C2 (enExample) |
| TW (1) | TW200513264A (enExample) |
| WO (1) | WO2005025605A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2449760C1 (ru) * | 2011-01-12 | 2012-05-10 | Светлана Минифаритовна Алетдинова | Способ лечения хронических верхушечных периодонтитов |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8113837B2 (en) | 2007-11-26 | 2012-02-14 | Peter John Zegarelli | Oral appliance for delivering a medicament |
| US8927284B2 (en) * | 2009-01-28 | 2015-01-06 | Organ Technologies, Inc. | Method for producing tooth |
| US8470303B2 (en) * | 2010-02-02 | 2013-06-25 | James C. Richards | Automated method and system for introducing molecular iodine into drinking water |
| US11273022B2 (en) | 2018-02-13 | 2022-03-15 | Emanate Biomedical, Inc. | Oral appliance in a blockchain system |
| US20190247173A1 (en) | 2018-02-13 | 2019-08-15 | Peter John Zegarelli | Methods of making an oral appliance |
| WO2019183201A1 (en) * | 2018-03-20 | 2019-09-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Regeneration of vital tooth pulp |
| US12440604B2 (en) | 2018-06-13 | 2025-10-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bone regeneration in compromised wounds |
| CN112220966A (zh) * | 2020-11-23 | 2021-01-15 | 北京大学口腔医学院 | 一种注射剂、注射剂的制备方法及其在牙髓再生中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
| US5372503A (en) * | 1993-04-27 | 1994-12-13 | Dental Marketing Specialists, Inc. | Method for installation of a dental implant |
| CA2187355C (en) * | 1994-04-08 | 2009-10-13 | Richard L. Dunn | An adjunctive polymer system for use with medical device |
| AU723740B2 (en) * | 1995-06-06 | 2000-09-07 | Howmedica Inc. | Biocompatible hydroxyapatite formulations and uses therefor |
| RU2096031C1 (ru) * | 1996-09-19 | 1997-11-20 | Акционерное общество "НИЗАР" | Средство для профилактики и лечения воспалительных заболеваний тканей пародонта |
-
2004
- 2004-09-08 JP JP2005513867A patent/JP4589233B2/ja not_active Expired - Fee Related
- 2004-09-08 EP EP04787706.3A patent/EP1671641B1/en not_active Expired - Lifetime
- 2004-09-08 EP EP12157314.1A patent/EP2460529B1/en not_active Expired - Lifetime
- 2004-09-08 CN CN201210032026.5A patent/CN102526706B/zh not_active Expired - Fee Related
- 2004-09-08 WO PCT/JP2004/013023 patent/WO2005025605A1/ja not_active Ceased
- 2004-09-08 CN CN201210032750.8A patent/CN102600455B/zh not_active Expired - Fee Related
- 2004-09-08 CN CN2004800311946A patent/CN1871024B/zh not_active Expired - Fee Related
- 2004-09-08 AU AU2004271843A patent/AU2004271843B2/en not_active Ceased
- 2004-09-08 RU RU2006111465/15A patent/RU2336089C2/ru active
- 2004-09-08 EP EP12157313.3A patent/EP2460528B1/en not_active Expired - Lifetime
- 2004-09-08 US US10/571,069 patent/US8158752B2/en not_active Expired - Fee Related
- 2004-09-09 TW TW093127310A patent/TW200513264A/zh unknown
-
2010
- 2010-06-24 JP JP2010143538A patent/JP5313209B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-05 US US13/412,503 patent/US8513191B2/en not_active Expired - Fee Related
- 2012-03-16 US US13/422,363 patent/US9089606B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2449760C1 (ru) * | 2011-01-12 | 2012-05-10 | Светлана Минифаритовна Алетдинова | Способ лечения хронических верхушечных периодонтитов |
Also Published As
| Publication number | Publication date |
|---|---|
| US9089606B2 (en) | 2015-07-28 |
| EP1671641B1 (en) | 2013-11-06 |
| JP5313209B2 (ja) | 2013-10-09 |
| EP1671641A1 (en) | 2006-06-21 |
| CN1871024B (zh) | 2012-03-28 |
| JPWO2005025605A1 (ja) | 2007-11-08 |
| CN1871024A (zh) | 2006-11-29 |
| US20120214738A1 (en) | 2012-08-23 |
| WO2005025605A1 (ja) | 2005-03-24 |
| JP2010215661A (ja) | 2010-09-30 |
| US8158752B2 (en) | 2012-04-17 |
| RU2006111465A (ru) | 2007-10-27 |
| EP2460528A1 (en) | 2012-06-06 |
| EP2460528B1 (en) | 2014-03-19 |
| US20120165255A1 (en) | 2012-06-28 |
| EP2460529A1 (en) | 2012-06-06 |
| CN102600455A (zh) | 2012-07-25 |
| AU2004271843A1 (en) | 2005-03-24 |
| RU2336089C2 (ru) | 2008-10-20 |
| CN102600455B (zh) | 2015-04-15 |
| TW200513264A (en) | 2005-04-16 |
| EP1671641A4 (en) | 2009-08-19 |
| US8513191B2 (en) | 2013-08-20 |
| AU2004271843B2 (en) | 2010-04-08 |
| EP2460529B1 (en) | 2014-08-20 |
| CN102526706A (zh) | 2012-07-04 |
| US20070071693A1 (en) | 2007-03-29 |
| CN102526706B (zh) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5313209B2 (ja) | 歯周病と歯髄疾患の治療剤と治療方法 | |
| Döri et al. | Effect of platelet‐rich plasma on the healing of intra‐bony defects treated with a natural bone mineral and a collagen membrane | |
| Nevins | Periodontal regeneration in human Class II furcations using purified recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with bone allograft | |
| Kalpidis et al. | Treatment of intrabony periodontal defects with enamel matrix derivative: a literature review | |
| Six et al. | Differential repair responses in the coronal and radicular areas of the exposed rat molar pulp induced by recombinant human bone morphogenetic protein 7 (osteogenic protein 1) | |
| Stavropoulos et al. | Growth and differentiation factors for periodontal regeneration: a review on factors with clinical testing | |
| Sato et al. | Enhanced cementum formation in experimentally induced cementum defects of the root surface with the application of recombinant basic fibroblast growth factor in collagen gel in vivo | |
| Döri et al. | Five‐year results evaluating the effects of platelet‐rich plasma on the healing of intrabony defects treated with enamel matrix derivative and natural bone mineral | |
| Conte et al. | Tissue engineering for periodontal regeneration | |
| JPH08501779A (ja) | モルフォゲン誘導歯周組織再生 | |
| JP7212144B2 (ja) | 非細胞性根管充填材および非細胞性歯組織再生促進キット | |
| Alharbi et al. | Unlocking the potential of cellular guidance in endodontics: advancing the process of pulp regeneration and beyond | |
| RU2368338C1 (ru) | Способ восстановления тканей пародонта | |
| Hsu et al. | Differential effects of parathyroid hormone, parathyroid hormone-related protein, and abaloparatide on collagen 1 expression by mouse cementoblasts and mouse tooth root density | |
| RU2812019C2 (ru) | Неклеточный наполнитель корневого канала и неклеточный набор, стимулирующий регенерацию тканей зуба | |
| Surisaeng | The use of modified mRNA encoding platelet-derived growth factor-BB as an innovation in periodontal regeneration | |
| Parimala | Comparative evaluation of bovine porous bone mineral (Bio-Oss) bone craft with and without platelet rich plasma (PRP) in the treatment of periodontal intrabony defects: a clinical study | |
| Sethi | Comparative evaluation of Bio-resorbable collagen membrane (Bio-gide perio) with and without autologous platelet-rich plasma (PRP) in the treatment of periodontal intrabony defects-a clinical study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100218 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100325 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100624 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100722 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100811 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100909 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4589233 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130917 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |